Adial Pharmaceuticals (ADIL) announced progress in the design and planning of its upcoming Phase 3 trial evaluating AD04, its lead investigational therapy for Alcohol Use Disorder. Highlights: Precision Phase 3 Planning: Post-hoc analyses of historical clinical trial data identified genotype-defined patient subgroups likely to benefit most from AD04. This supports Adial’s precision medicine approach in the upcoming Phase 3 trial-targeting higher efficacy and commercial differentiation. Data-Driven, Adaptive Trial Design: Adial partnered with Cytel to apply advanced statistical analytics and simulation modelling to support a more efficient and targeted Phase 3 strategy, including machine learning and proprietary tools such as East to optimize the trial design, enable adaptive enrichment, and align with regulatory expectations. Upcoming Milestones: The precision-focused Phase 3 trial is expected to begin in late 2025, with potential for interim analysis-driven readouts, supporting a streamlined path to potential regulatory submission.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADIL:
- Adial Pharmaceuticals files to sell 7.59M shares of common stock, warrants
- Adial Pharmaceuticals Faces Nasdaq Non-Compliance Notice
- Adial Pharmaceuticals files to sell 6.73M shares of common stock for holders
- Adial Pharmaceuticals Sets 2025 Annual Meeting Date
- Adial Pharmaceuticals expects cash to fund operations into Q4 of 2025